4.63
-0.15 (-3.04%)
| Previous Close | 4.77 |
| Open | 4.85 |
| Volume | 39,863 |
| Avg. Volume (3M) | 57,014 |
| Market Cap | 29,842,350 |
| Price / Book | 8.34 |
| 52 Weeks Range | |
| Earnings Date | 12 May 2025 - 16 May 2025 |
| Diluted EPS (TTM) | -7.36 |
| Total Debt/Equity (MRQ) | 566.73% |
| Current Ratio (MRQ) | 1.99 |
| Operating Cash Flow (TTM) | -27.36 M |
| Levered Free Cash Flow (TTM) | -18.79 M |
| Return on Assets (TTM) | -48.51% |
| Return on Equity (TTM) | -576.46% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | KALA BIO, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 4.0 |
| Average | 1.13 |
|
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA’smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 1.91% |
| % Held by Institutions | 64.18% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 33.00 (Oppenheimer, 613.51%) | Buy |
| Median | 31.50 (581.08%) | |
| Low | 30.00 (Mizuho, 548.65%) | Buy |
| Average | 31.50 (581.08%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 15.74 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Oppenheimer | 11 Sep 2025 | 33.00 (613.51%) | Buy | 17.00 |
| Mizuho | 08 Sep 2025 | 30.00 (548.65%) | Buy | 14.48 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Sep 2025 | Announcement | KALA BIO to Present at H.C. Wainwright 27th Annual Global Investment Conference |
| 02 Sep 2025 | Announcement | KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director |
| 08 Aug 2025 | Announcement | KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update |
| 09 Jul 2025 | Announcement | KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) |
| 07 Jul 2025 | Announcement | KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |